#16
|
||||
|
||||
À ìíå êàæåòñÿ, ÷òî ïðîñòî êàæäîìó ñâîé ñïèñîê ïîäõîäèò
|
#17
|
||||
|
||||
Âû îøèáàåòåñü.
__________________
×òîáû ïîñòàâèòü äèàãíîç íåïðàâèëüíî, íàäî èìåòü îñîáûé òàëàíò è ïðåìíîãî ïîñòàðàòüñÿ: ñäåëàòü ÌÐÒ è ÊÒ âñåõ ëþáîïûòíûõ ìåñò áîëüíîãî, ðåíòãåíîâñêèå ñíèìêè îò ãîëîâû äî ïÿò, àíàëèçû âñåõ áèîæèäêîñòåé, ïðèãëàñèòü ïÿòîê-äðóãîé êîíñóëüòàíòîâ… Ñàì ÷åðò ïîòîì âî âñåì ýòîì íå ðàçáåðåòñÿ! Ï. Ðóäè÷ |
#18
|
||||
|
||||
Êàæäûé âûáèðàåò äëÿ ñåáÿ
æåíùèíó, ðåëèãèþ, äîðîãó. (Þðèé Ëåâèòàíñêèé) Îò ñåáÿ äîáàâëþ: Íåâåæäàì - åñòåñòâåííûé îòáîð! |
#19
|
|||
|
|||
Ïðîøó ïðîùåíèÿ, à åñëè äåéñòâèòåëüíî ïîäõîäèò? Äà, ïóñòü ïëàöåáî. Íó è ÷òî? Òà æå ïñèõîòåðàïèÿ, êîòîðóþ, ê ñîæàëåíèþ, çäåñü ëþáÿò íàçíà÷àòü ïðè âñåõ íåïîíÿòíûõ áîëåçíÿõ - òîæå ïëàöåáî. È íè÷åãî, íèêòî ïî÷åìó-òî íå êðèòèêóåò. À åñëè ðàñêðèòèêîâàííûé âäîëü è ïîïåð¸ê ïèðàöåòàì êîãî-òî ñòàâèò íà íîãè, òî, ìîæåò, ïëåâàòü íà ôîðìàëüíîñòè ÷òî "íå äîêàçàíî"?
|
#20
|
|||
|
|||
Î÷åíü ñòðàííî, ÷òî â ýòîò ñïèñîê ïîïàëè Êåïïðà è Äåïàêèí Õðîíî (íîìåð 117). Âàëüïðîåâàÿ êèñëîòà(Äåïàêèí, Êîíâóëåêñ, Êóíâóëüñîôèí) - ýòî óíèâåðñàëüíîå ïðîòèâîýïèëåïòè÷åñêîå ñðåäñòâî, ýôôåêòèâíî èñïîëüçóþùååñÿ ïðè ýïèëåïñèè ñ 60-õ ãîäîâ XX âåêà. Î äîêàçàòåëüíîé áàçå äàæå ñìåøíî ãîâîðèòü... Òûñÿ÷è èññëåäîâàíèé è òîííû ëèòåðàòóðû.  ïñèõèàòðèè âàëüïðîåâàÿ êèñëîòà îáîñíîâàííî ïðèìåíÿåòñÿ â êà÷åñòâå íîðìîòèìè÷åñêîãî ñðåäñòâà ïðè ðàññòðîéñòâàõ àôôåêòà. ×òî æå êàñàåòñÿ ïðåïàðàòà Êåïïðà(ëåâåòèðàöåòàì), òî ýòî îäíî èç ñðàâíèòåëüíî íîâûõ ïðîòèâîýïèëåïòè÷åñêèõ ñðåäñòâ, çàðåãèñòðèðîâàííîå â ÑØÀ â 1999 ãîäó (ó íàñ - â 2003 ãîäó) è îáëàäàþùåå íå òîëüêî õîðîøåé ïåðåíîñèìîñòüþ, íî è è ðÿäîì âàæíåéøèõ ïðåèìóùåñòâ, çíà÷èòåëüíî ðàñøèðÿþùèõ åãî êëèíè÷åñêîå ïðèìåíåíèå ïðè ýïèëåïñèè.
|
#21
|
||||
|
||||
Öèòàòà:
Çà÷åì òàê ìíîãî âîçìóùåíèé? Ïðîñòî, ïîæàëóéñòà, äàéòå ññûëêè íà ïîñëåäíèå ãàéäû è èñïûòàíèÿ ñ ýòèìè ïðåïàðàòàìè. |
#22
|
|||
|
|||
Åùå îäèí ïîäîáíûé ñïèñîê [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#23
|
|||
|
|||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Levetiracetam*for partial seizures: results of a double-blind, randomized clinical trial). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Multicenter double-blind, randomized, placebo-controlled trial of*levetiracetam*as add-on therapy in patients with refractory partial seizures. European*Levetiracetam*Study Group) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Efficacy and tolerability of*levetiracetam*3000 mg/d in patients with refractory partial seizures: a*multicenter,double-blind, responder-selected study evaluating monotherapy. European*Levetiracetam*Study Group). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Efficacy and safety of*levetiracetam*(up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: amulticenter,*randomized,*double-blind,*placebo-controlled*study). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Once-daily extended-release*levetiracetam*as adjunctive treatment of partial-onset seizures in patients with epilepsy: a*double-blind,*randomized,*placebo-controlled*trial). Èññëåäîâàíèÿ ïî ýôôåêòèâíîñòè ëåâåòèðàöåòàìà â ïåäèàòðè÷åñêîé ïðàêòèêå: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Double-blind*placebo-controlled*trial*of adjunctive*levetiracetam*in pediatric partial seizures). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Adjunctive*levetiracetam*in infants and young children with refractory partial-onset seizures). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Levetiracetam*as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two*randomized,*double-blind,*placebo-controlled*studies). Èññëåäîâàíèå ïî íàëè÷èþ ïîëîæèòåëüíîãî íåéðîêîãíèòèâíîãî ýôôåêòà ó ëåâåòèðàöåòàìà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Neurocognitive effects of adjunctive*levetiracetam*in children with partial-onset seizures: a*randomized,*double-blind,*placebo-controlled, noninferiority*trial). Åñòåñòâåííî, ÿ ïðèâ¸ë äàëåêî íå âñå èññëåäîâàíèÿ, äîêàçûâàþùèå ýôôåêòèâíîñòü ëåâåòèðàöåòàìà ïðè ýïèëåïñèè. |
#24
|
|||
|
|||
Öèòàòà:
Ýôôåêòèâíîñòü íîâûõ àíòèýïèëåïòè÷åñêèõ ïðåïàðàòîâ äîêàçûâàþò ïðèñîåäèíåíèåì èõ ê áàçîé òåðàïèè âàëüïðîàòàìè (1+ âàëüïðîàò), ïðèñîåäèíåíèåì ê äâóì (èëè òðåì) ïðåïàðàòàì ïðè ðåçèñòåíòíûõ ôîðìàõ ýïèëåïñèè (1+1+âàëüïðîàò), ñðàâíèâàÿ èõ ñ ýôôåêòèâíîñòüþ ïðèñîåäèíÿåìîãî ê áàçîâîé òåðàïèè ïëàöåáî â êîíòðîëüíûõ ãðóïïàõ. Íà "ÏàáÌåä'å" ìíîæåñòâî ïîäîáíûõ èññëåäîâàíèé. À âîò íåêîòîðûå èññëåäîâàíèÿ ïî íàëè÷èþ íîðìîòèìè÷åñêîãî ýôôåêòà ó âàëüïðîàòà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Valproate*as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective,randomized,*double-blind,*placebo-controlled,*multicenter*study. European*Valproate*Mania Study Group). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder). |
#25
|
||||
|
||||
Óâàæàåìûé AlexisZuboff!
Ñïàñèáî. ß âû÷åðêíó ó ñåáÿ èç ñïèñêà ýòè ïðåïàðàòû è ñîîáùó ññûëêó íà Âàøè ññûëêè, íà ñàéò ñ êîòîðîãî ýòîò ñïèñîê âçÿë. |
#26
|
||||
|
||||
Öèòàòà:
...adjunctive levetiracetam on memory and attention as measured by validated and well-standardized neurocognitive instruments were no different from placebo in children aged 4–16 years with inadequately controlled partial-onset seizures.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#29
|
||||
|
||||
Êàê ïîíèìàþ, ýòî èññëåäîâàíèå ôàçû 2:
"This study was planned as an exploratory phase II trial. This design limits the degree of evidence obtained; thus, the results should be confirmed in a large-scale phase III trial." êàê áû ïîäòâåðæäàþùåå íà ïðåäâàðèòåëüíîé ñòàäèè òå äàííûå, êîòîðûå áûëè ïîëó÷åíû ðàíåå ïðè àíàëèçå ïîäãðóïï [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] åùå ìîìåíòû - âëèòî áûëî ñâûøå ïîëëèòðû ãèäðîëèçàòà â òå÷åíèå òðåõ íåäåëü (òî åñòü åñëè ââîäèòü ïî 5-10 ìë 10-15 äíåé â çàâèñèìîñòè îò ôèí. âîçìîæíîñòåé ïàöèåíòà, òî íå ôàêò, ÷òî ýôôåêò áóäåò èäåíòè÷åí) ïëþñ ðåàáèëèòàöèîííàÿ ïðîãðàììà (áóäåò ëè ñåé ýôôåêò, åñëè ðåàáèëèòàöèþ íå ïðîâîäèòü â äîëæíîì îáüåìå - íåèçâåñòíî). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#30
|
||||
|
||||
Ýêñïåðèìåíòû íà ãðûçóíàõ êàê ðàç è ïîêàçûâàþò äîçîçàâèñèìûé ýôôåêò, êîòîðûé íà÷èíàåòñÿ ñ 2.5 ìë/êã, ÷òî â ðàç 5-6 íèæå, íåæåëè ïðèìåíåííûå âûøå äîçû (30 ìë íà 60-80 êã âçðîñëîãî):
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |